COX-2 inhibitors--lessons in drug safety

N Engl J Med. 2005 Mar 17;352(11):1133-5. doi: 10.1056/NEJMe058042. Epub 2005 Feb 15.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Cardiovascular Diseases / chemically induced*
  • Celecoxib
  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors / adverse effects*
  • Cyclooxygenase Inhibitors / therapeutic use
  • Drug Approval / legislation & jurisprudence*
  • Gastrointestinal Hemorrhage / chemically induced
  • Gastrointestinal Hemorrhage / prevention & control
  • Humans
  • Isoxazoles / adverse effects
  • Lactones / adverse effects
  • Membrane Proteins
  • Prostaglandin-Endoperoxide Synthases
  • Publishing / standards
  • Pyrazoles / adverse effects
  • Randomized Controlled Trials as Topic / standards*
  • Research Design
  • Sulfonamides / adverse effects
  • Sulfones / adverse effects
  • United States
  • United States Food and Drug Administration / organization & administration*

Substances

  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • Isoxazoles
  • Lactones
  • Membrane Proteins
  • Pyrazoles
  • Sulfonamides
  • Sulfones
  • rofecoxib
  • valdecoxib
  • parecoxib
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases
  • Celecoxib